Preclinical studies showed that mice treated with SIRT1 agonists exhibited bone loss resistance in different osteoporosis models, suggesting SIRT1 as an attractive pharmacological target to counteract bone loss in aging [58]. Here, SIRT1 is linked to osteoporosis.